2nd Line Colorectal Cancer
Español  |  中國傳統的  |  简体中文
Call us  (855) 528-7322
Main Menu

2nd Line Colorectal Cancer

Sponsor: Boston Biomedical, Inc

A Study comparing FOLFIRI chemotherapy to FOLFIRI chemotherapy plus a Napabucasin, which is a new agent targeting cancer stem cells, in patients with colon or rectal cancer